Speech-Language Pathologists in Lake Ariel, PA Accepting Medicare
4 Speech-Language Pathologists found. Showing 1 - 4
 Susan O'shea, M.S.SLPCCC Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 1404 Golf Park Dr, Lake Ariel, PA 18436 Phone: 570-698-5647 Fax: 570-698-7742 |
Tamara Ann Dobrzyn Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 126 Hidden Valley Dr, Lake Ariel, PA 18436 Phone: 570-851-8379 |
Kerri Mazur Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 1404 Golf Park Dr, Lake Ariel, PA 18436 Phone: 570-698-5647 |
Dakota Kyzer Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 112 N Shore Ln, Lake Ariel, PA 18436 Phone: 570-616-2855 |
News Archive
New strategies and approaches to treat patients with hypertension
While studies of hypertension have been performed worldwide in a variety of epidemiological settings such as diabetes, renal function, obesity and thyroid disorders, there is a need to identify appropriate treatment strategies.
Study looks at health care in 21 countries
A new study involving health care systems in 21 countries - and the prospects for change in response to such common pressures as rising costs and aging populations - casts doubt on the possibility of major overhauls of any of these systems because of the history and traditions that created them.
Middle East respiratory syndrome coronavirus currently unlikely to cause a pandemic, finds study
New estimates of the transmissibility of the Middle East respiratory syndrome coronavirus (MERS-CoV) in humans suggest that it does not yet have pandemic potential, according to research published in The Lancet.
Nutrient "floodgate" protects against inflammatory immune response
After every meal, the body must prevent the immune system from launching an all-out fight against food.
Regulus' RG-012 receives orphan medicinal product designation in EU for treatment of Alport syndrome
Regulus Therapeutics Inc., a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, announced today that the European Commission has granted orphan medicinal product designation for RG-012, a single stranded, chemically modified oligonucleotide that binds to and inhibits the function of microRNA-21 ("miR-21") for the treatment of Alport syndrome, a life-threatening genetic kidney disease with no approved therapy.
› Verified 4 days ago
Speech-Language Pathologists
Occupational Therapists
Chiropractors
Optometrists
Physical Therapists